Research

Research into the causes and development of bronchiectasis, as well as its diagnosis and treatment, is the focus of current research.

Research activities

Based on the data from the PROGNOSIS Registry and the biobank, the establishment of further basic research-oriented and translational projects is already underway and continues to be planned.

Through intensified research activities, the topic of NCFB is expected to play an increasingly prominent role at national and international congresses.

Prof. Dr. Tobias Welte and Prof. Dr. Felix Ringshausen, both from Hannover Medical School, contributed as German representatives to the development of the European guideline “European Respiratory Society clinical practice guideline for the management of adult bronchiectasis” as part of the ERS Task Force.

A consensus-based German-language, trinational guideline (AT-CH-DE) on the management of adult patients with bronchiectasis was also developed under the leadership of the German Respiratory Society (Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V., DGP; guideline coordination and scientific leadership: Prof. Dr. Felix Ringshausen, Hannover Medical School).

Publications in German

Management der Primären Ciliären Dyskinesie

Raidt, J., Brillault, J., Brinkmann, F., Jung, A., Koerner-Rettberg, C., Koitschev, A., Linz-Keul, H., Nüßlein, T., Ringshausen, F. C., Röhmel, J., Rosewich, M., Werner, C. and Omran, H.

Pneumologie (Nov 2020)

Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie

Lommatzsch, M., Rabe, K. F., Taube, C., Joest, M., Kreuter, M., Wirtz, H., Blum, T. G., Kolditz, M., Geerdes-Fenge, H., Otto-Knapp, R., Häcker, B., Schaberg, T., Ringshausen, F. C., Vogelmeier, C. F., Reinmuth, N., Reck, M., Gottlieb, J., Konstantinides, S., Meyer, F. J., Worth, H., Windisch, W., Welte, T. and Bauer, T.

Pneumologie (Nov 26 2020)

S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Modul 2: Diagnostik und Therapie bei der chronischen Infektion mit Pseudomonas aeruginosa

Schwarz, C., Schulte-Hubbert, B., Bend, J., Abele-Horn, M., Baumann, I., Bremer, W., Brunsmann, F., Dieninghoff, D., Eickmeier, O., Ellemunter, H., Fischer, R., Grosse-Onnebrink, J., Hammermann, J., Hebestreit, H., Hogardt, M., Hugel, C., Hug, M., Illing, S., Jung, A., Kahl, B., Koitschev, A., Mahlberg, R., Mainz, J. G., Mattner, F., Mehl, A., Moller, A., Muche-Borowski, C., Nusslein, T., Puderbach, M., Renner, S., Rietschel, E., Ringshausen, F. C., Schmidt, S., Sedlacek, L., Sitter, H., Smaczny, C., Tummler, B., Vonberg, R., Wielputz, M. O., Wilkens, H., Wollschlager, B., Zerlik, J., Duesberg, U. and van Koningsbruggen-Rietschel, S.

Pneumologie (May 2018)

Messung des nasalen Stickstoffmonoxids und ein modifizierter PICADAR-Score als Screening für primär ciliäre Dyskinesie in Erwachsenen mit Bronchiektasen

Rademacher, J., Buck, A., Schwerk, N., Price, M., Fuge, J., Welte, T. and Ringshausen, F. C.

Pneumologie (Aug 2017)

Lungenerkrankung durch nichttuberkulöse Mykobakterien

Ringshausen FC, Rademacher J.

Internist (Berl). 2016;57(2):142-52

Aktuelle Übersicht Bonchiektasen

Rademacher J, Ringshausen FC.

COPD in Deutschland. 2015 Aug; 50-52

PROGNOSIS – The PROspective German NOn-CF BronchiectaSIS Patient Registry

Rademacher J, de Roux A, Ringshausen FC.

Pneumologie. 2015 Jul;69(7):391-3

Therapie von Bronchiektasen

Rademacher J, Schweigert M.

Zentralbl Chir. 2015 Feb;140(1):113-26; quiz 127-8

Nicht durch eine zystische Fibrose bedingte (Non-CF-) Bronchiektasen

Ringshausen FC, Rademacher J, Welte T.

Dtsch Med Wochenschr. 2014 Apr;139(14):707-10

Non-CF-Bronchiektasen mit Fokus auf die allergische bronchopulmonale Aspergillose

Rademacher J, Ringshausen FC.

Pneumologie. 2013 Jan; 67(1):40-7; 48-9

Bronchiektasen – Diagnostik und Therapie

Rademacher J, Welte T.

Dtsch Arztebl Int. 2011 Dec;108(48):809-15

Einführung zum Thema Bronchiektasen

Ringshausen FC, Welte T.

Der Pneumologe. 2014/4

Leitthema Epidemiologie von Non-CF-Bronchiektasen

Rademacher J, Ringshausen FC.

Pneumologe. 2014/4

Leitthema Diagnostik von Bronchiektasen

Dr. N. Derichs.

Pneumologe. 2014/4

Leitthema Atemtherapie bei Non-CF-Bronchiektasen

Brückner U.

Pneumologe. 2014/4

Leitthema Pneumologische Rehabilitation bei Non CF-Bronchiektasen

Glöckl R, Kenn K.

Pneumologe. 2014/4

Leitthema Inhalative Antibiotikatherapie bei Non-CF-Bronchiektasen

Flick H, Meilinger M, Wagner M, Olschewski H, Eber E.

Pneumologe. 2014/4

Leitthema Versorgung von Patienten mit Non-CF-Bronchiektasen in der niedergelassenen Praxis

de Roux A.

Pneumologe. 2014/4

Publications in English

On the website of the European Bronchiectasis Registry EMBARC, you will find a selection of current publications in English:

Selection

Recent studies

To date, only a few controlled studies have been conducted, meaning that it is difficult to provide evidence-based recommendations for non-CF bronchoscopies.

The efficacy of many different substances is currently being investigated. A hypertonic saline solution is frequently used in clinical practice, as it has been shown to be beneficial in CF, although this has not yet been proven for non-CF bronchiectasis.

Following positive results from Phase II trials, inhaled mannitol is now in Phase III clinical trials.

Inhaled antibiotics may be of particular significance in patients colonised with Gram-negative pathogens. Tobramycin and colistin are established – albeit not approved – whilst aztreonam, ciprofloxacin and gentamicin are being tested in clinical trials. According to the results of several studies – albeit with only small sample sizes – macrolides appear to have an additional beneficial effect. Long-term therapy with inhaled antibiotics and/or macrolides is only indicated if a clearly positive effect is observed within three months of starting treatment (reduction in sputum volume, freedom from exacerbations).

ERADICATE STUDY

For doctors

Care for patients with frequent exacerbations (German)

An interview with Dr Felix C. Ringshausen and Prof. Tobias Welte